Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

Qingqing Cai, Yi Xia, Xiaojie Fang, Man Nie, Qihua Zou, Jun Cai, Yuchen Zhang, Qiuyi Yang, Dawei Ding, Wen Wang, Xunqiang Wang

Blood (2024) 144 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2024-203156

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Journal Articles

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Qingqing Cai, Yi Xia, Huiqiang Huang, Ying Zhao, Fan Yang, Wenning Xu, Hongyan Tong, Chunmei Yang, Xiaojie Fang, Man Nie, Yu Fang, Gao Yan, Xuanye Zhang, Rong Tao, Xiuhua Sun, Xueyi Pan, Tao Wu, Yuchen Zhang, Jun Cai

Blood (2024) 144 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2024-206564

Published: 2024

Journal Articles

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Qingqing Cai, Yi Xia, Dongfeng Zeng, Xi Li, Xiaojie Fang, Man Nie, Xiaopeng Tian, Lirong Li, Yingxian Liu

Blood (2024) 144 (Supplement 1): 7779.

https://doi.org/10.1182/blood-2024-206953

Published: 2024

Journal Articles

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Xiao Lu, Yeqin Sha, Xinyu Song, Luomengjia Dai, Ziyuan Zhou, Hanning Tang, Yi Miao, Shuchao Qin, Yi Xia, Tonglu Qiu, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2024) 144 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2024-207729

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2023-189681

Published: 2023

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2023-188925

Published: 2023

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Qingqing Cai, Yi Xia, Liang Wang, Huiqiang Huang, Jinni Wang, Jun Cai, Xiaopeng Tian

Blood (2023) 142 (Supplement 1): 4470.

https://doi.org/10.1182/blood-2023-188430

Published: 2023

Journal Articles

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Gao Yan, Qingqing Cai, Zhiming Li, Xiaoxiao Wang, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2023-181619

Published: 2023

Journal Articles

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

Yi Miao, Siqi Qian, Xiao Lu, Tonglu Qiu, Shuchao Qin, Yi Xia, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2023) 142 (Supplement 1): 6083.

https://doi.org/10.1182/blood-2023-182617

Published: 2023

Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2023-189110

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Elderly Patients with Stage I Diffuse Large B-Cell Lymphoma: A Study By Jiangsu Cooperative Lymphoma Group (JCLG)

Blood (2023) 142 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2023-181373

Published: 2023

Journal Articles

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li

Blood (2022) 140 (Supplement 1): 6985–6987.

https://doi.org/10.1182/blood-2022-169720

Published: 2022

Journal Articles

A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study

Qingqing Cai, Yi Xia, Hui Zhou, Wenyu Li, Zhiming Li, Xu Ye, Yudan Wu, Huo Tan, Runhui Zheng, Bingyi Wu, Hui Yang, Yuhong Lu, Yang Liang, Ning Su, Qihua Zou, Panpan Liu

Blood (2022) 140 (Supplement 1): 9450–9451.

https://doi.org/10.1182/blood-2022-166080

Published: 2022

Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4117–4118.

https://doi.org/10.1182/blood-2022-170985

Published: 2022

Journal Articles

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Huiqiang Huang, Yan Gao, Guowei Li, Xiuhua Sun, Xueyi Pan

Blood (2022) 140 (Supplement 1): 9356–9357.

https://doi.org/10.1182/blood-2022-166237

Published: 2022

Journal Articles

Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Qihua Zou, Jun Cai

Blood (2022) 140 (Supplement 1): 12035–12036.

https://doi.org/10.1182/blood-2022-156400

Published: 2022

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4164–4165.

https://doi.org/10.1182/blood-2022-170815

Published: 2022

Journal Articles

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Qingqing Cai, Panpan Liu, Yi Xia, Jun Cai, Huiqiang Huang, Zhiming Li, Hui Zhou, Yajun Li, Hanyu Wang, Ying Huang, Gao Yan, Xueyi Pan

Blood (2022) 140 (Supplement 1): 2299–2301.

https://doi.org/10.1182/blood-2022-168457

Published: 2022

NARROW

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Clinical Characteristics and Outcomes of Elderly Patients with Stage I Diffuse Large B-Cell Lymphoma: A Study By Jiangsu Cooperative Lymphoma Group (JCLG)

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only